Our team’s studies on tumor-specific T-cell immune responses in HCC patients showed that: compared with the advanced stage, HCC patients with early-stage had broad-spectrum immunity and high-intensity SMNMS (SALL4, MAGE-A3, NY-ESO-1, MAGE-A1, SSX2) specific T cell immune responses, which could delay tumor recurrence after ablation (22). This evidence concerns the gene MAGEA3 and hepatocellular carcinoma.